Yu Miura

1.1k total citations
46 papers, 748 citations indexed

About

Yu Miura is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Yu Miura has authored 46 papers receiving a total of 748 indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Oncology, 31 papers in Pulmonary and Respiratory Medicine and 5 papers in Immunology. Recurrent topics in Yu Miura's work include Lung Cancer Treatments and Mutations (28 papers), Cancer Immunotherapy and Biomarkers (26 papers) and Lung Cancer Diagnosis and Treatment (14 papers). Yu Miura is often cited by papers focused on Lung Cancer Treatments and Mutations (28 papers), Cancer Immunotherapy and Biomarkers (26 papers) and Lung Cancer Diagnosis and Treatment (14 papers). Yu Miura collaborates with scholars based in Japan, United Kingdom and Australia. Yu Miura's co-authors include Kyoichi Kaira, Hiroshi Kagamu, Kunihiko Kobayashi, Ou Yamaguchi, Ayako Shiono, Kosuke Hashimoto, Atsuto Mouri, Yoshitake Murayama, Fuyumi Nishihara and Hisao Imai and has published in prestigious journals such as Cancer Research, Scientific Reports and Annals of Oncology.

In The Last Decade

Yu Miura

44 papers receiving 742 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yu Miura Japan	17	570	380	175	78	72	46	748
Takatoshi Fujishita Japan	13	554 1.0×	370 1.0×	97 0.6×	58 0.7×	99 1.4×	32	793
Ou Yamaguchi Japan	19	910 1.6×	677 1.8×	207 1.2×	78 1.0×	132 1.8×	88	1.1k
Marta Batus United States	13	296 0.5×	243 0.6×	74 0.4×	51 0.7×	178 2.5×	60	569
Marcelo V. Negrão United States	15	491 0.9×	449 1.2×	66 0.4×	61 0.8×	223 3.1×	65	769
Atsuto Mouri Japan	16	520 0.9×	385 1.0×	86 0.5×	72 0.9×	51 0.7×	72	677
Shinsuke Saisho Japan	17	407 0.7×	321 0.8×	159 0.9×	87 1.1×	93 1.3×	47	722
Daniel Eiger Belgium	13	451 0.8×	189 0.5×	71 0.4×	106 1.4×	125 1.7×	34	595
Masahiro Morise Japan	17	707 1.2×	752 2.0×	68 0.4×	63 0.8×	206 2.9×	112	1.1k
Carina Hillenbach Switzerland	7	383 0.7×	319 0.8×	34 0.2×	99 1.3×	111 1.5×	11	630
Shotaro Kato Japan	5	292 0.5×	136 0.4×	76 0.4×	80 1.0×	51 0.7×	14	418

Countries citing papers authored by Yu Miura

Since Specialization

Citations

This map shows the geographic impact of Yu Miura's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yu Miura with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yu Miura more than expected).

Fields of papers citing papers by Yu Miura

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yu Miura. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yu Miura. The network helps show where Yu Miura may publish in the future.

Co-authorship network of co-authors of Yu Miura

This figure shows the co-authorship network connecting the top 25 collaborators of Yu Miura. A scholar is included among the top collaborators of Yu Miura based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yu Miura. Yu Miura is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Endo, Satoshi, Hisao Imai, Atsuto Mouri, et al.. (2025). Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology. 151(1). 43–43. 2 indexed citations

Kaira, Kyoichi, Hisao Imai, Ayako Shiono, et al.. (2025). Prognostic factors of liver metastases in extensive-stage small cell lung cancer receiving chemo-immunotherapy. Translational Lung Cancer Research. 14(5). 1569–1581. 1 indexed citations

Hashimoto, Kosuke, Kyoichi Kaira, Atsuto Mouri, et al.. (2025). Metabolic tumor volume on 18F-FDG uptake as a negative predictor after ipilimumab plus nivolumab in advanced non-small cell lung cancer. Translational Lung Cancer Research. 14(4). 1242–1253.

Shiono, Ayako, Hisao Imai, Satoshi Endo, et al.. (2024). A retrospective evaluation of therapeutic efficacy and safety of chemoradiotherapy in older patients (aged ≥ 75 years) with limited-disease small cell lung cancer: insights from two institutions and review of the literature. Radiology and Oncology. 58(3). 432–443. 2 indexed citations

Ito, Koki, Kyoichi Kaira, Ou Yamaguchi, et al.. (2024). Clinical impact of inflammatory and nutrition index based on metabolic tumor activity in non‑small cell lung cancer treated with immunotherapy. Oncology Letters. 27(3). 110–110. 4 indexed citations

Horinouchi, Hidehito, Isao Yokota, Teppei Yamaguchi, et al.. (2024). Durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non–small‐cell lung cancer (NEJ056). Cancer Science. 115(11). 3705–3717. 1 indexed citations

Endo, Satoshi, Hisao Imai, Ayako Shiono, et al.. (2024). The Glasgow Prognostic Score as a Predictor of Survival after Chemoradiotherapy for Limited-Disease Small Cell Lung Cancer. Oncology. 103(2). 1–11.

Yamaguchi, Ou, Norimitsu Kasahara, Hiroshi Soda, et al.. (2023). Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib. Scientific Reports. 13(1). 20848–20848. 5 indexed citations

Kaira, Kyoichi, Hisao Imai, Atsuto Mouri, et al.. (2023). Clinicopathological impact of VEGFR2 and VEGF‐C in patients with EGFR‐major mutant NSCLC receiving osimertinib. Thoracic Cancer. 14(29). 2950–2961. 3 indexed citations

10.

Yamaguchi, Ou, Kyoichi Kaira, Hisao Imai, et al.. (2023). Clinical Utility of Inflammatory and Nutritious Index as Therapeutic Prediction of Nivolumab plus Ipilimumab in Advanced Non-Small Cell Lung Cancer. Oncology. 102(3). 271–282. 10 indexed citations

11.

Kagamu, Hiroshi, Shigehisa Kitano, Ou Yamaguchi, et al.. (2022). Single-Cell Analysis Reveals a CD4+ T-cell Cluster That Correlates with PD-1 Blockade Efficacy. Cancer Research. 82(24). 4641–4653. 27 indexed citations

12.

Abe, Takanori, Satoshi Saitô, Tomohiro Ohta, et al.. (2022). Simple method for evaluating achievement degree of lung dose optimization in individual patients with locally advanced non‐small cell lung cancer treated with intensity modulated radiotherapy. Thoracic Cancer. 13(20). 2890–2896. 4 indexed citations

13.

Mouri, Atsuto, Kyoichi Kaira, Ou Yamaguchi, et al.. (2021). Efficacy and Feasibility of Programmed Death-1/Programmed Death Ligand-1 Blockade Therapy in Non-Small Cell Lung Cancer Patients With High Antinuclear Antibody Titers. Frontiers in Oncology. 11. 610952–610952. 11 indexed citations

14.

Abe, Takanori, Nao Kobayashi, Satoshi Saitô, et al.. (2020). Pattern of Local Failure and its Risk Factors of Locally Advanced Non-small Cell Lung Cancer Treated With Concurrent Chemo-radiotherapy. Anticancer Research. 40(6). 3513–3517. 6 indexed citations

15.

Saitô, Satoshi, Takanori Abe, Nao Kobayashi, et al.. (2020). Incidence and dose-volume relationship of radiation pneumonitis after concurrent chemoradiotherapy followed by durvalumab for locally advanced non-small cell lung cancer. Clinical and Translational Radiation Oncology. 23. 85–88. 25 indexed citations

16.

Yamaguchi, Ou, Kyoichi Kaira, Kosuke Hashimoto, et al.. (2020). Tumor metabolic volume by 18F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50%. Scientific Reports. 10(1). 14990–14990. 24 indexed citations

17.

Kagamu, Hiroshi, Shigehisa Kitano, Ou Yamaguchi, et al.. (2019). CD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy. Cancer Immunology Research. 8(3). 334–344. 169 indexed citations

18.

Yamaguchi, Ou, Kyoichi Kaira, Atsuto Mouri, et al.. (2019). Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation. Cancer Chemotherapy and Pharmacology. 83(5). 817–825. 12 indexed citations

19.

Noshiro, Takao, et al.. (1994). Angiotensin II enhances norepinephrine spillover during sympathetic activation in conscious rabbits. American Journal of Physiology-Heart and Circulatory Physiology. 266(5). H1864–H1871. 7 indexed citations

20.

Miura, Yu, et al.. (1992). QT prolongation with torsade de pointes in pheochromocytoma. American Heart Journal. 124(1). 235–239. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact